Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as a therapy for the chronic lung condition. It may soon become the first-ever FDA-approved treatment for bronchiectasis.
Quelle: ScienceDaily | Asthma
Titelbild/Grafik: ScienceDaily News
Weiteres von ScienceDaily | Asthma
- Doctors tested a common drug on COVID. The results are stunning
- New inhaler halves childhood asthma attacks
- One number at age 7 could predict how long you live
- More likely to be struck by lightning than get tetanus. So why the boosters?
- Invisible ID: How a single breath could reveal your health—and your identity
- People with critical cardiovascular disease may benefit from palliative care
- Study links childhood trauma to increased substance use and unexpected effects on heart rate and blood pressure in adolescents
- Study identifies new method for improving lung growth and function in preterm infants
- Highly accurate blood test diagnoses Alzheimer's disease, measures extent of dementia
- Global warming can lead to inflammation in human airways, new research shows
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
